Effect Of Robotic Rehabilitation And Vagus Nerve Stimulation In Ischemia Stroke Patients
Launched by SEFA HAKTAN HATIK · Apr 19, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of two types of treatments for patients who have had an ischemic stroke, which is a type of stroke caused by a blockage of blood flow to the brain. The trial focuses on robotic rehabilitation, which helps patients regain movement and strength, and vagus nerve stimulation, a non-invasive method that sends gentle electrical signals through the ear to possibly improve recovery. The goal is to see how these treatments can help patients improve their walking ability, muscle function, and overall quality of life.
To be eligible for this study, participants must be adults over 18 years old who have experienced their first ischemic stroke within the last six months and have some difficulty moving on one side of their body (hemiparesis). They should be able to walk, even with support, and must be able to understand and participate in the rehabilitation exercises. Throughout the trial, participants will receive treatment for six weeks and will be assessed on their progress, including their walking speed and muscle activity. This study aims to provide valuable insights into improving recovery for stroke patients, and those interested in participating will need to meet specific health criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being diagnosed with ischemic stroke
- • Having a stroke for the first time
- • Having hemiparesis
- • ≤ 6 months after stroke
- • Being able to walk with or without support
- • Understanding and focusing on Lokomat exercises and being able to do them
- • Having received walking training with Lokomat in our hospital
- • Having signed the voluntary consent form
- • Being over 18 years of age
- Exclusion Criteria:
- • Body weight more than 135 kg
- • The person's height is more than two meters
- • Femur length outside the range of 35-47 cm
- • Intolerable leg length differences
- • Peripheral nerve injury
- • Peripheral neuropathy
- • Anticholinergic drug use
- • Presence of skin lesions
- • Spasticity that prevents the locomotive from working
- • Having diagnosed psychiatric problems
- • Severe contracture in lower extremity muscles
- • Not being able to walk before stroke
- • Having a history of additional neurological diseases (Parkinson, etc.)
- • Unstable cardio-pulmonary disease
- • Having orthopedic fractures (lower extremity fractures) and/or joint implants
- • Severe osteoporosis
- • Uncontrolled hypertension despite medication use
- • Lower extremity amputation
About Sefa Haktan Hatik
Sefa Haktan Hatik is a dedicated clinical trial sponsor specializing in innovative research and development within the pharmaceutical and biotechnology sectors. With a focus on advancing medical science, the organization is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards and regulatory guidelines. By fostering collaboration among multidisciplinary teams, Sefa Haktan Hatik aims to accelerate the discovery and delivery of new therapies, ultimately enhancing patient care and outcomes. Their expertise in trial design, patient recruitment, and data management positions them as a leader in the pursuit of transformative healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
SEFA HAKTAN HATIK, PhD
Study Chair
Sinop University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported